Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Sheri A. Lippman, Alyssa C. Mooney, Scott Barnhart, Jessica S Grignon, Hailey J. Gilmore, Teri Liegler, Gillian Hunt, Hong-Ha M. Truong, Lisa M. Prach, Adrian Puren
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Infectious Diseases, vol 20, iss 1
BMC infectious diseases, vol 20, iss 1
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Infectious Diseases, vol 20, iss 1
BMC infectious diseases, vol 20, iss 1
Background Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective. We examine the contribution of drug resistance mutations for low
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-7 (2020)
Background Vancomycin-resistant enterococcus (VRE) is an important cause of infection in immunocompromised populations. Few studies have described the characteristics of vanB VRE infection. We sought to describe the epidemiology, treatment and outcom
Autor:
Tshepiso Mbangiwa, Sajini Souda, Simani Gaseitsiwe, Lynnette Bhebhe, Wonderful T. Choga, Pinkie Melamu, Edward Zumbika, Sikhulile Moyo, Max Essex, Rosemary Musonda, Bonolo B. Phinius, Chabeni C. Banda, Jason T. Blackard, Motswedi Anderson, Zachary M. Shaver
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-6 (2019)
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-6 (2019)
Background Hepatitis C virus (HCV) infection is a major cause of chronic liver disease globally. Direct acting antivirals (DAAs) have proven effective in curing HCV. However, the current standard of care (SOC) in Botswana remains PEGylated interferon
Autor:
Taramasso, L., Tatarelli, Paola, Ricci, Elena, Madeddu, G., Menzaghi, B., Squillace, Nicola, De Socio, G. V., Martinelli, C., Gulminetti, Roberto, Maggi, P., Orofino, G., Vichi, F., Di Biagio, A., Bonfanti, Paolo, Bellacosa, C., Calza, L., Abeli, C., Celesia, B. M., Grosso, C., Stagno, A., Mazzotta, F., Penco, G., Cassola, G., Nicolini, L. A., Dentone, C., Molteni, C., Palvarini, L., Scalzini, A., Carenzi, L., Rizzardini, G., Valsecchi, L., Cordier, L., Rusconi, S., Colombo, Valeria, Galli, M., Franzetti, M., Sgrelli, A., Mazzotta, E., Parruti, G., Bagella, P., Mura, M. S., Libertone, R., Antinori, A., Di Giambenedetto, S., Guastavigna, M., Caramello, P.
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-8 (2018)
Background: Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-bas
Autor:
Nadia Galizzi, Andrea Poli, Marco Ripa, Vincenzo Spagnuolo, Nicola Gianotti, Adriano Lazzarin, Silvia Nozza, Alessia Carbone, Antonella Castagna, Marco Merli, Laura Galli
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-8 (2017)
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-8 (2017)
Background Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durab
Autor:
Salem Gugsa, Tom Heller, Petros Tembo, Richard Broadhurst, Robertino Lim, Christopher C. Stanley, Hannock Tweya, Sam Phiri, Colin Speight, Dennis Ongubo, Mina C. Hosseinipour, McNeil Ngongondo
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-10 (2017)
Background Malawi’s national antiretroviral therapy program provides atazanavir/ritonavir–based second line regimens which cause concentration-dependent rise in indirect bilirubin. We sought to determine if elevated bilirubin, as a surrogate of a
Autor:
Marie-Claude Gagnieu, Patrick Miailhes, Jean-Michel Livrozet, Fabien Zoulim, François Parant, François Bailly, Marianne Maynard, Pierre Chiarello, Giorgiana Hatu, Pierre Pradat, Emmanuel Pourcelot
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, 2014, 14 (1), pp.150. ⟨10.1186/1471-2334-14-150⟩
BMC Infectious Diseases, BioMed Central, 2014, 14 (1), pp.150. ⟨10.1186/1471-2334-14-150⟩
BMC Infectious Diseases, 2014, 14 (1), pp.150. ⟨10.1186/1471-2334-14-150⟩
BMC Infectious Diseases, BioMed Central, 2014, 14 (1), pp.150. ⟨10.1186/1471-2334-14-150⟩
International audience; BACKGROUND: In HIV infected patients, the impact of ribavirin (RBV) pharmacology on sustained virologic response (SVR) to hepatitis C virus (HCV) treatment has not been fully investigated. The objective of this study was to co
Autor:
Jyoti Aggarwal, Stephen Bubb, Carly Dougher, Lauren Fusfeld, Montserrat Vera-Llonch, Mrudula Donepudi, Thomas F. Goss
Publikováno v:
BMC Infectious Diseases
Background Infection with hepatitis C virus (HCV) is associated with high morbidity and increased mortality but many patients avoid initiation of treatment or report challenges with treatment completion. The study objective was to identify motivators
Autor:
Jens Bukh, Peer Brehm Christensen, Niels Obel, Nina Weis, Nanna Hansen, Alex Lund Laursen, Henrik Krarup, Poul Schlichting, Axel Møller, Mette S Kjær
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 11, Iss 1, p 177 (2011)
Hansen, N, Obel, N, Christensen, P B, Kjær, M, Laursen, A L, Krarup, H B, Møller, A, Schlichting, P, Bukh, J O D, Weis, N, the Danish Database for Hepatitis B and C (DANHEP)-group & Nielsen, H I 2011, ' Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study ', B M C Infectious Diseases, vol. 11, no. 1, pp. 177 . https://doi.org/10.1186/1471-2334-11-177
Hansen, N, Obel, N, Christensen, P B, Kjær, M, Laursen, A L, Krarup, H B, Møller, A, Schlichting, P, Bukh, J O D, Weis, N & DANHEP Group 2011, ' Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study ', B M C Infectious Diseases, vol. 11, pp. 177 . https://doi.org/10.1186/1471-2334-11-177
BMC Infectious Diseases, Vol 11, Iss 1, p 177 (2011)
Hansen, N, Obel, N, Christensen, P B, Kjær, M, Laursen, A L, Krarup, H B, Møller, A, Schlichting, P, Bukh, J O D, Weis, N, the Danish Database for Hepatitis B and C (DANHEP)-group & Nielsen, H I 2011, ' Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study ', B M C Infectious Diseases, vol. 11, no. 1, pp. 177 . https://doi.org/10.1186/1471-2334-11-177
Hansen, N, Obel, N, Christensen, P B, Kjær, M, Laursen, A L, Krarup, H B, Møller, A, Schlichting, P, Bukh, J O D, Weis, N & DANHEP Group 2011, ' Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study ', B M C Infectious Diseases, vol. 11, pp. 177 . https://doi.org/10.1186/1471-2334-11-177
Background The effect of peginterferon and ribavirin treatment on chronic hepatitis C virus (HCV) infection has been established in several controlled clinical studies. However, the effectiveness of treatment and predictors of treatment success in ro
Autor:
Lars Hagberg, Aylin Yilmaz, Magnus Gisslén, Lars Ståhle, Jan-Olof Svensson, Ulrika Nillroth, Dietmar Fuchs
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 6, Iss 1, p 63 (2006)
BMC Infectious Diseases, Vol 6, Iss 1, p 63 (2006)
Background The way various antiretroviral drugs and drug combinations affect HIV-1 infection in the central nervous system is still largely unknown. The aim of this study was to determine the cerebrospinal fluid (CSF) steady-state concentrations of s